Cardiac Comorbidities Start Early in RA and SpA


An increased risk of cardiovascular disease is present in early rheumatoid arthritis and early spondyloarthritis, new research shows.

Rheumatoid arthritis and spondyloarthritis are often accompanied by an increased risk of cardiovascular disease. Now, new research finds that this risk is present in even the early stages of each disease.

​The study found that patients with rheumatoid arthritis or spondyloarthritis are more likely than the general population to have a history of tuberculosis. Doctors should watch for cardiac comorbidities and tuberculosis history immediately upon diagnosis, researchers say in anextended report published in the Sept. 14 issue of the journal RMD Open.

Led by Désirée van der Heijde, a professor of rheumatology at Leiden University Medical Center in the Netherlands, the researchers analyzed the comorbidities of 689 patients with early rheumatoid arthritis (ERA) and 645 patients with early axial spondyloarthritis (ESpA) from two research cohorts in France. For early rheumatoid arthritis, the diagnosis had to have occurred within the previous six months; for early axial spondyloarthritis, within less than three years.


What was known: CVD and infections, particularly tuberculosis, are frequently associated with established rheumatoid arthritis and with spondyloarthritis.

What this study adds: The risk of CVD and tuberculosis is increased even in early-stage arthritis, after long periods of inflammation and after prolonged treatment with corticosteroids or immunosuppressive drugs.

What this means for clinical practice: Patients at risk should be screened and treated for comorbidities early.


Source: RMD Open

Overall, 42.7 percent of early rheumatoid arthritis patients and 20.3 early axial spondyloarthritis patients had at least one comorbidity, the researchers found. Arterial hypertension was the most common among early rheumatoid arthritis patients (18.2%), followed by dyslipidaemia (17.7%), dysthyroid (11.9%), tuberculosis (4.6%) and malignancies (4.1%). [[{"type":"media","view_mode":"media_crop","fid":"41853","attributes":{"alt":"©SebastianKaulitzki/","class":"media-image media-image-right","id":"media_crop_9133733697235","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4484","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"font-size: 13.008px; line-height: 1.538em; float: right;","title":" ","typeof":"foaf:Image"}}]]

Among early axial spondyloarthritis patients, dyslipidaemia was the most common comorbidity (9.3%), followed by arterial hypertension (5.1%) and ulcer (4%).

Many of these comorbidities are common in the population as a whole. However, some appeared more frequently in the arthritic patients. In particular, arterial hypertension among early rheumatoid arthritis patients (18.2% (15.5% to 21.3%, confidence interval (CI) 95%)) was significantly higher than the general French population level of 7.58% (p<0.05), the researchers reported.

"This increase was noticeable especially in younger women (45–64 years), when CVD risk in the general population is generally low," the researchers wrote.

Likewise, the prevalence of tuberculosis was higher in both ERA and EsPA than in the general population. The prevalence of tuberculosis was 4.7% in early rheumatoid arthritis patients (3.3% to 6.6%, 95% CI) and 1% in early axial spondyloarthritis (0.4% to 2.3%, 95% CI). In comparison, the rate among the general French population was 0.02%, a significant difference (p<0.05).  The link between RA, SpA and tuberculosis is not entirely clear, though a 2015 study in mice found that tuberculosis infection can enhance arthritis, van der Heijde and her colleagues wrote.

The researchers also studied typical cardiovascular risk factors in the two patient groups, calculating Framingham scores for 313 ERA patients and 333 ESpA patients.  Overall, they found low 10-year cardiovascular disease risk (8.3% in ERA patients and 3.7% in ESpA patients), but older ERA patients stuck out as having elevated risk. Among men over age 55, the risk of developing cardiovascular disease within 10 years was greater than 20%, considered high-risk. Women older than 60 carried an intermediate risk of between 10% and 20%.

What's more, patients with ERA had "heart ages" between 4 and 10 years older than their chronological age, the data suggested. The mean heart rate age for patients between the ages of 30 and 69 was 53.8, plus or minus 15.6 years. ESpA patients had a smaller mean increase in heart age over actual age of 2.1, plus or minus 7 years.

"Our results suggest that established RA and ERA should be regarded as a condition at high risk of CVD and that there is need for early CV risk evaluations," the researchers wrote.

Previous research has found that chronic inflammation is the culprit linking rheumatoid arthritis to heart disease, but the current study did not detect any link between inflammation and cardiovascular risk factors early in the disease. Nevertheless, doctors should be on the lookout for comorbidities, particularly cardiovascular problems, the researchers wrote. They suggest using the concept of heart age to explain long-term risk to young patients.

The patient data on ERA came from the French Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) cohort. The ESpA data was from the Devenir des Spondylarthropathies Indifférenciées Récentes (DESIR) cohort. Information on the general French population came from the Caisse Nationale d’Assurance Maladie des Travailleurs Salariés, or CNAMTS, France's national health insurance service for salaried workers.


Related Articles from Rheumatology Network




Gherghe AM, Dougados M, et al.

Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts.

RMD Open

2015;1: e000128. doi:10.1136/rmdopen-2015-000128 

Related Videos
Noortje van Herwaarden, MD, PhD | Credit: St Maartens Medical Center
Related Content
© 2023 MJH Life Sciences

All rights reserved.